LataMed AI Corp. (OTC: LMEDD) announced today that its previously announced 5-for-1 forward stock split has become effective at the opening of trading following publication on the FINRA Daily List dated July 14, 2026. The company's common stock began trading under the temporary symbol LMEDD, which is expected to remain for approximately twenty business days before reverting to LMED. The forward stock split is implemented in conjunction with a mandatory share exchange and a new CUSIP number, 21116R404, while the prior CUSIP, 21116R305, is suspended.
The forward stock split, a corporate action that increases the number of outstanding shares proportionally, is typically used by companies to adjust share price and potentially improve liquidity. For LataMed AI, this move comes as the company focuses on expanding its telemedicine platform and pursuing commercialization opportunities for its artificial intelligence platforms, including CardioAI, PulmoAI, and NeuroAI. CEO Dr. Kevin Rodan Levy emphasized that the split represents an important corporate milestone and expressed appreciation for shareholder support as the company executes its long-term strategy.
Shareholders holding shares through brokerage accounts or in electronic book-entry form are generally not required to take any action, as brokerage firms and custodians are expected to process the corporate action automatically. Those holding physical stock certificates are not required to immediately surrender them, but when presented for transfer, sale, or exchange, they will be processed under the mandatory exchange procedures and exchanged for the appropriate number of post-split shares under the new CUSIP.
The announcement is significant for investors as it reflects LataMed AI's efforts to align its capital structure with its growth objectives. The company, a development-stage digital health and AI technology firm, is building telehealth infrastructure and AI-enabled healthcare solutions for emerging markets, with an initial focus on Latin America. The forward stock split may also signal confidence in the company's future prospects and its ability to attract investment as it advances its technology platforms.
LataMed AI encourages shareholders with questions to contact their brokerage firm or the company's transfer agent. For additional information, shareholders can visit https://latamed.ai or review filings with the U.S. Securities and Exchange Commission at www.sec.gov.
